Early initiation of statin treatment in children with familial hypercholesterolaemia

Current Opinion in Pediatrics

Volumn 26, Issue 3, 2015, Pages 236-239

  Braamskamp, Marjet J A M ^a,b   Hutten, Barbara A ^a   Wiegman, Albert ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Pediatrics ^*  (Netherlands)

Author keywords

children; familial hypercholesterolemia; prevention of cardiovascular disease; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CHILD; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEADACHE; HUMAN; LIFESTYLE MODIFICATION; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIBLING; COMPLICATION; HYPERLIPOPROTEINEMIA TYPE II; TREATMENT OUTCOME; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; LONG TERM CARE;

ATHEROSCLEROSIS; CHILD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; PRAVASTATIN; TREATMENT OUTCOME;

EID: 84960074993     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000177     Document Type: Review

References (19)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill Information Services Company; 2001. pp. 2863-2913.
2. Innerarity TL, Weisgraber KH, Arnold KAYS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84:6919-6923.
3. Abifadel M, Rabè s J-P, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30:520-529.
4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
5. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560-565.
6. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171:309-325.
7. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363:369-370.
8. De Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:2117-2121.
9. Narverud I, Retterstøl K, Iversen PO, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis 2014; 235:299-309.
10. Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res 2014; 114:307-310.
11. Braamskamp MJ, Langslet G, Mccrindle BW, et al. Effect of rosuvastatin therapy on arterial wall changes in children and adolescents with familial hypercholesterolemia: results from the CHARON study. EAS 2014; Madrid, Spain.
12. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 (Suppl):S213-S256.
13. Malhotra A, Shafiq N, Arora A, et al. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014; 6:CD001918.
14. Guardamagna O, Abello F, Baracco V, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol 2011; 48:127-133.
15. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218:272-280.
16. Braamskamp MJ, Langslet G, Mccrindle BW, et al. Efficacy and safety of rosuvastatin therapy for children and adolescents with heterozygous familial hypercholesterolemia: results from the CHARON study. EAS 2014; Madrid, Spain.
17. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27:1803-1810.
18. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014; 312:1055-1057.
19. Braamskamp MJ, Kusters DM, Avis HJ, et al. Patients with familial hypercholesterolemia who initiated statin treatment in childhood are at lower risk for CHD than their affected parents. AHA Dallas 2013, Abstract 17837.